Modelling of signalling via G-protein coupled receptors: Pathway-dependent agonist potency and efficacy

A mathematical model is constructed to study promiscuous coupling of receptors to G-proteins and to simulate events leading to the activation of multiple effector pathways within a cell. The model is directed at a better understanding of the factors that determine the efficacy and potency of a drug. Assuming that the receptors can exist in multiple conformational states, and allowing for agonist specific conformation, a system of ordinary differential equations is constructed and subsequently pathway-dependent agonist efficacy and potency order is predicted. A simple case of the compartmentalization of receptors and G-proteins is also given, using the current model to illustrate the effects of spatial heterogeneity on the predicted response.

[1]  J. Dickenson,et al.  Influence of receptor number on functional responses elicited by agonists acting at the human adenosine A(1) receptor: evidence for signaling pathway-dependent changes in agonist potency and relative intrinsic activity. , 2000, Molecular pharmacology.

[2]  R. Emeson,et al.  RNA‐editing of the 5‐HT2C receptor alters agonist‐receptor‐effector coupling specificity , 2001, British journal of pharmacology.

[3]  P. Leff,et al.  A three-state receptor model of agonist action. , 1997, Trends in pharmacological sciences.

[4]  V. Vlachova,et al.  Modelling the consequences of receptor-G-protein promiscuity. , 2002, Trends in pharmacological sciences.

[5]  R. Lefkowitz,et al.  A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. , 1980, The Journal of biological chemistry.

[6]  W. Vaz.  Diffusion and chemical reactions in phase-separated membranes. , 1994, Biophysical chemistry.

[7]  R. Neubig,et al.  Timing is everything the role of kinetics in G protein activation. , 2000, Life sciences.

[8]  J. Linderman,et al.  Compartmentalization of Receptors and Enzymes Affects Activation for a Collision Coupling Mechanism , 1998 .

[9]  R. Seifert,et al.  Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.

[10]  L. Brunton,et al.  Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. , 2001, Annual review of pharmacology and toxicology.

[11]  S. Hill,et al.  Mechanisms of Cross-Talk between G-Protein-Coupled Receptors , 2002, Neurosignals.

[12]  T. Kenakin,et al.  THE CUBIC TERNARY COMPLEX RECEPTOR-OCCUPANCY MODEL. II. UNDERSTANDING APPARENT AFFINITY , 1996 .

[13]  R. Ostrom,et al.  New determinants of receptor-effector coupling: trafficking and compartmentation in membrane microdomains. , 2002, Molecular pharmacology.

[14]  Terry Kenakin,et al.  Drug efficacy at G protein-coupled receptors. , 2002, Annual review of pharmacology and toxicology.

[15]  P. Morgan,et al.  The Cubic Ternary Complex ReceptorOccupancy Model I. Model Description , 1996 .

[16]  R. Lefkowitz,et al.  A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.

[17]  J. Linderman,et al.  Modeling activation and desensitization of G-protein coupled receptors provides insight into ligand efficacy. , 1999, Journal of theoretical biology.

[18]  T. Kenakin,et al.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. , 1995, Trends in pharmacological sciences.

[19]  P. Leff,et al.  Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. , 1998, Molecular pharmacology.